ABSTRACT
【Objective】 To investigate the effects of atosiban combined with ritodrine hydrochloride on clinical efficacy， serological indicators and maternal and infant outcomes of patients with threatened premature delivery. 【Methods】 A total of 138 patients with threatened preterm delivery in the Department of Obstetrics and Gynecology of The First Affiliated Hospital of Air Force Military Medical University from June 2018 to June 2020 were collected and divided into two groups according to random number table method， with 69 patients in the control group treated with ritodrine hydrochloride and 69 patients in the study group treated with atosiban on the basis of the control group. Clinical efficacy， changes in serological indicators， maternal and child outcomes， and drug safety were compared between the two groups. 【Results】 There were 65 effective cases in the study group （94.20%） and 56 effective cases in the control group （81.16%）. There were statistically significant differences between the two groups （P0.05）. After treatment， timp-1， il-8， il-6， NO and PGE2 levels in the study group were significantly lower than those in the control group （P<0.05）. The success rate of fetal preservation， gestational age， neonatal weight and Apgar score were significantly higher in the study group than in the control group， while the rate of premature delivery was significantly lower than that in the control group （P<0.05）. The incidence of drug-induced adverse reactions （5.80%） was significantly lower in the study group than in the control group （26.09%） （P<0.05）. 【Conclusion】 Atosiban combined with ritodrine hydrochloride can effectively prolong pregnancy， reduce the level of serological indicators， improve maternal and infant outcomes， with fast effect， safe and significant efficacy. Therefore， it is worthy of application and promotion in the treatment of patients with threatened premature delivery.
ABSTRACT
<b>Objective: </b>In Japan, the healthcare authority encourages physicians to prescribe generic drugs in order to reduce the copayments by the patients for pharmaceutical expenses and to improve the financial status of the national medical insurance system. In accordance with this governmental policy, we have been actively involved in switching original to generic formulations. Thus, Utemerine® 50 mg injection was replaced with Ritodrine hydrochloride 50 mg intravenous injection produced by Nichiiko. There have been some reports on adverse events caused by the generic formulations of Ritodrine hydrochloride. Factors contributing to these adverse effects may include different additives and/or vehicles and the exemption of demonstrating some conditions for approval, including clinical trials. Therefore, in order to assess the efficacy and safety of a generic formulation of Ritodrine hydrochloride injection formulation compared with the original formulation and to decide on its continued use, we carried out a retrospective cohort study.<br><b>Methods: </b>We carried out a retrospective cohort study in order to assess the efficacy and safety of a generic formulation of Ritodrine hydrochloride injection formulation compared with the original formulation.<br><b>Results: </b>There were no significant differences in the length of hospital stay, rate of emergency transport to other institutions, gestational week of delivery, rate of stillbirth, rate of abortion, or incidence of adverse events between the two formulations.<br><b>Conclusion: </b>Our results may contribute to the safe and secure use of the generic formulations of Ritodrine hydrochloride in the current situation of the increasing use of generic drugs in health care. Although there are some limitations in our study, the results suggest that there are no particular problems with the continued use of Ritodrine hydrochloride 50 mg intravenous injection produced by Nichiiko.
ABSTRACT
Objective To study clinical observation and nursing on ritodrine hydrochloride for the treatment of premature. Methods 92 pregnant women with threatened preterm labor in our hospital (February 2016 to December 2017) were randomly divided into the control group and the experimental group,each with 46 cases. The control group were treated with Magnesium Sulfate, the experimental group were treated with ritodrine hydrochloride. The experimental group and the control group were given reasonable nursing measures, and the relative clinical indexes of the two groups were compared and analyzed. Results After the corresponding treatment, the duration of pregnancy in the experimental group was (16.20±12.00) days, and the body weight of the newborn was (2.93±0.35) kg, which was significantly better than that of the control group, with statistical significance(P<0.05). Two groups of patients did not have obvious adverse reactions, nausea, vomiting, headache and other adverse reactions were 10.00% and 12.00% respectively, and there was no statistical significance. The effective rate of the experimental group was 91.30%, which was significantly higher than that of the control group (65.20%), which was statistically significant (P<0.05). Conclusion Clinical curative effect of ritodrine hydrochloride for treatment of preterm birth is ideal, can significantly improve patients' clinical symptoms, high safety.
ABSTRACT
Objective To study clinical observation and nursing on ritodrine hydrochloride for the treatment of premature. Methods 92 pregnant women with threatened preterm labor in our hospital (February 2016 to December 2017) were randomly divided into the control group and the experimental group,each with 46 cases. The control group were treated with Magnesium Sulfate, the experimental group were treated with ritodrine hydrochloride. The experimental group and the control group were given reasonable nursing measures, and the relative clinical indexes of the two groups were compared and analyzed. Results After the corresponding treatment, the duration of pregnancy in the experimental group was (16.20±12.00) days, and the body weight of the newborn was (2.93±0.35) kg, which was significantly better than that of the control group, with statistical significance(P<0.05). Two groups of patients did not have obvious adverse reactions, nausea, vomiting, headache and other adverse reactions were 10.00% and 12.00% respectively, and there was no statistical significance. The effective rate of the experimental group was 91.30%, which was significantly higher than that of the control group (65.20%), which was statistically significant (P<0.05). Conclusion Clinical curative effect of ritodrine hydrochloride for treatment of preterm birth is ideal, can significantly improve patients' clinical symptoms, high safety.
ABSTRACT
Objective To observe the effect of ritodrine hydrochloride on peripheral blood and tocolysis rate of patients with threatened premature labor.Methods89 cases of patients with threatened premature labor were selected from October 2015 to September 2016 and randomly divided into two groups, research group with 45 cases treated with ritodrine hydrochloride and control group with 44 cases treated with epsom salt.The peripheral blood, extinction time of uterine contraction, extended days of pregnancy, postpartum hemorrhage, neonatal birth weight and tocolysis rate were compared between two groups.ResultsAfter treatment, CRH, NO, PGE2 and IL-8 of control group were obviously higher than research group, the difference was statistically significant (t=10.826,3.839,7.534,8.075,P0.05).The overall efficacy of tocolysis in control group was 70.5%, while that in research group was 86.7%, which was obviously higher than the control group, the difference was statistically significant (χ2=7.801,P<0.05).ConclusionRitodrine hydrochloride can effectively control uterine contraction factor in peripheral blood and extend gestational days of patients with threatened premature labor, so as to improve tocolysis rate and birth quality.
ABSTRACT
Objective To study the psychological intervention combined with ritodrine hydrochloride and observe the effect of Magnesium Sulfate threatened abortion after 20 weeks of treatment. Methods 100 pregnant women with threatened abortion in our hospital from February 2015 to October 2016 were selected and randomly divided into control group and experimental group. Each group had 50 cases. the control group was treated with Magnesium Sulfate treatment, experimental group was treated with ritodrine hydrochloride treatment, psychological intervention, pay attention to mental health, strengthen the communication with patients. Results After the corresponding treatment, the SAS score of the experimental group was (40.1±6.2) points, and the SDS score was (38.4±7.9) points. The scores of SAS and SDS in the control group were (49.6±7.2) points, (48.2±8.5) points. After treatment, 5 patients in the experimental group had adverse reactions, and the incidence of adverse reactions was 10%. Adverse reactions occurred in 13 patients in the control group. The adverse reaction rate in the control group (26.0%) was significantly higher than that in the experimental group (10.0%), with statistical difference (P<0.05). The weight of the newborn, the duration of pregnancy and the onset time of the drug in the experimental group were better than those in the control group (P<0.05). Conclusion Psychological intervention combined with ritodrine hydrochloride and Magnesium Sulfate have good clinical effect on the treatment of threatened abortion after 20 weeks of gestation, can visibly improve patients' depression and anxiety, with further clinical promotion and application significance.
ABSTRACT
Objective To study the analysis of ritodrine hydrochloride in comparison with Magnesium Sulfate expect application effect in the treatment of placenta previa.Methods In Wenling Maternal and Child Health Care Department from January 2014 to December 2016 were 100 cases of expectant treatment of placenta previa patients as the research object in the course of the study, were randomly divided into control group and experimental group two were 50 cases each.The control group was treated with the Magnesium Sulfate treatment, patients in the experimental group of ritodrine hydrochloride.A comparative analysis of the experimental group and the control group of patients with successful pregnancy, prolonged pregnancy and neonatal weight and other indicators, including the adverse reactions of patients.Results After the treatment,the number of success cases in experimental group was 48 cases, the success rate was 96%,the number of cases to 42 cases stopped bleeding during pregnancy, to extend the time for(16.2±12.0)days, neonatal weight(3.21±0.35)kg.The number of cases of successful pregnancy control group of patients was 41 cases, the success rate was 82%,the number of cases to 36 cases stopped bleeding during pregnancy, to extend the time for(12.2±10.2)days, neonatal weight(2.39±0.48)kg.Available, the experimental group success time extension of pregnancy and neonatal weight were significantly better than the control group, with statistical difference(P<0.05).Can be obtained, the experimental group and the control group, the incidence of adverse reactions were statistically significant.Conclusion Ritodrine hydrochloride and Magnesium Sulfate expect application effect in the treatment of placenta previa compared the clinical effect of ritodrine hydrochloride, can effectively improve the indicators for further promotion and application, has the clinical significance.
ABSTRACT
Objective To discuss curative effect between ritodrine hydrochloride and magnesium sulfate treated with threatened premature labor and its effect to fetal fibronectin .Methods 368 cases threatened premature labor puerperants were selected and randomly divided into the ritodrine hydrochloride treatment group ( short for obser-vation group) and magnesium sulfate treatment group (short for control group),The two group puerperants′curative effect,changes of fetal fibronectin positive rate and safety evaluation were observed .Results Compared with the con-trol group,the observation group′s medicine effect time ,treatment failure proportion obviously decreased;prolongation pregnancy days,treatment success proportion obviously increased ,the differences all had statistical significances (t=103.4,9.6,χ2 =12.0,all P0.05);after the treatment,the observation group′s fFN positive rates was 28.26%,wich of the control group was 42.39%,compared the two groups′fFN positive rates,the observa-tion group obviously decreased ,the differences had statistical significances (χ2 =8.0,P <0.05).The observation group′s untoward effect rate was 1 9 .5 7%, which was lower than that of the control group (χ2 =4 .8 , P<0 .0 5 ) .Conclusion Ritodrine hydrochloride treated with threatened premature labor not only can get good treatment effect , shorten medicine effect time ,prolong pregnancy days;but also can obviously decrease fetal fibronectin positive rate , which has good safety ,and is suitable for clinical application .
ABSTRACT
A forties year-old female visited our hospital on March 2011, complaining chest discomfort. Computed tomography (CT) revealed a huge mass in the anterior mediastinum combined with multiple masses in the lungs, the uterus and the bone. Since no abnormal shadow had been noticed on the chest radiograph on January 2011,they seemed to have grown very rapidly in a short period. The pathological diagnosis following needle biopsies of mediastinal and uterine cervix tumors was undifferentiated carcinoma of the thymus metastasizing to the uterus. She was also suffering from the pain on the right femur and intermittent hypogastralgia due to metastases to the bone and uterus. Although NSAIDs and oxicodone relieved the pain on the right femur, they could not significantly reduce the hypogastralgia. Judging from the nature of the frightful hypogastralgia, the cause was estimated to be not somatalgia but splanchnodynia. Ritodorine hydrochloride, which was then adnimistered for the purpose of inhibiting the contraction of the uterine, was remarkably effective in reducing the pain. According to the literatures reviewed concerning metastases of the extrapelvic malignant tumors to the uterus, the median survival period after occurrence of metastases was 14 months. This report suggests that the administration of Ritodorine hydrochloride can keep the quality-of-life of these patients without suffering from the pain due to metastatic tumor to the uterus.
ABSTRACT
It is essential to prolong the term as possible in the treatment of threatened premature delivery. We report a case of threatened abortion successfully treated with hochuekkito. The patient was 31 year-old pregnant woman with lower abdominal pain. She was diagnosed to be at the risk of premature delivery on 21 weeks and 5 days of gestation. Intravenous ritodrine hydrochloride was started and she had to stay in bed. Severe side effects of ritodrine hydrochloride such as palpitation, tachycardia, tremor, nausea, and loss of appetite were appeared and she was consulted to our department on 23 weeks and 1 day of gestation. Those symptoms were markedly improved after administration of hochuekkito extract. She delivered a male infant of 1230g birth weight on 28 weeks of gestation. Hochuekkito suppressed severe side effects, and enabled to continue the infusion of ritodrine hydrochloride, suggesting the usefulness of Kampo therapy in the treatment of threatened premature delivery.
ABSTRACT
Ritodrine hydrochloride (Yutopar) is commonly used for the treatment of preterm labor. Published reports claim that many complications of prematurity have been averted by the administration of this drug. However, ritodrine hydrochloride has many side effects, including cardiovascular problem and metabolic error. Only a few reports have described the transient hepatitis (elevated transaminase) all over the world. The clinical significance and incidence of this side effect are still unclear. In this report, we present a case of elevated serum transaminase levels associated with the use of ritodrine during pregnancy with a brief review of the literatures.
Subject(s)
Female , Pregnancy , Hepatitis , Incidence , Obstetric Labor, Premature , RitodrineABSTRACT
OBJECTIVE: This study was conducted to compare the efficacy and safety of oral nicardipine in acute therapy for preterm labor with those of parenteral ritodrine hydrochloride. METHODS: Patients between 24 and 34 weeks' gestation with documented preterm labor were randomly assigned to receive oral nicardipine (n=31) or intravenous ritodrine (n=32) as initial tocolytic therapy. Patients in the nicardipine group received a 40-mg loading dose and then 20 mg every 2 hours as needed to stop contractions (total 80 mg). Patients in the ritodrine group received a 0.05 mg/min as initial dose. The dose was increased at 15-minute intervals until uterine contractions were inhibited or side effects became intolerable. The maximum recommended dose was 0.35 mg/min. Patients could be switched to another tocolytic regimen if they continued to have contractions after 6 hours of therapy. The main outcome variables examined were failure of tocolysis, time to uterine contractions equal or less than 5 times per hour, time to uterine quiescence, time gained in utero, and frequency of adverse medication effects. RESULTS: There were no significant differences in maternal demographic characteristics between the groups. Successful tocolysis, defined as cessation of uterine contractons less than 6 hours from initial dose, was observed in 58.1% in the nicardipine group and 65.6% in the ritodrine group (P=.544). Among patients with successful tocolysis who responded with uterine quiescence within 6 hours, there was no significant difference in the time to uterine quiescence in the ritodrine group (P=.087). Time to uterine contractions equal or less than 5 times per hour from initial treatment showed no significant difference between the two groups with successful tocolysis (P=.097). The patients in the ritodrine hydrochloride group had more adverse side effects, mainly maternal tachycardia (P=.013) and nausea and/or vomiting (P=.006). CONCLUSION: Oral nicardipine was effective, safe, and well-tolerated tocolytic agent. Patients who received ritodrine hydrochloride were more likely to have adverse medication effects.
Subject(s)
Female , Humans , Pregnancy , Nausea , Nicardipine , Obstetric Labor, Premature , Ritodrine , Tachycardia , Tocolysis , Uterine Contraction , VomitingABSTRACT
OBJECTIVE: This study was designed to compare the efficacy and safety of the ritodrine hydrochloride alone with combined treatment with magnesium sulfate in the management of preterm labor. METHODS: One hundred thirty three singleton pregnancies with preterm labor were treated with either ritodrine hydrochloride (n=97) or ritodrine hydrochloride and magnesium sulfate (n=36). The principal outcomes assessed were delay of duration, maternal-fetal side effects, and fetal outcome. RESULTS: The treatment to delivery time was not statistically different between the ritodrine group and the combined magnesium sulfate group (mean+/-SD 10.7+/-13.0 days, 8.6+/-9.1 days, respectively). The proportion delivered after 48 hours, 72 hours, or 7 days was also not statistically different between two groups (29% vs. 22%, 40% vs. 39%, 60% vs. 64%, respectively). No statistical difference was found in the side effects of treatment or fetal outcomes. CONCLUSION: There was no significant difference in efficacy and safety between ritodrine hydrochloride and combined treatment with magnesium sulfate in the management of preterm labor.
Subject(s)
Female , Pregnancy , Magnesium Sulfate , Magnesium , Obstetric Labor, Premature , RitodrineABSTRACT
OBJECTIVES: The aim of this study was to compare the efficacy and safety of magnesium sulfate, ritodrine hydrochloride and nifedipine in the management of preterm labor. MATERIALS AND METHODS: 180 women with documented preterm labor were randomly assigned to receive magnesium sulfate (n=60), ritodrine hydrochloride (n=60) and nifedipine (n=60) as initial tocolytic therapy. 30 women with documented preterm labor were allocated to administer fluid only and bed rest as control group. Patient could be switched to another tocolytic regimen if they continued to have contractions or side effects. The main outcome variables examined were days gain in utero, success rate, side effects and neonatal outcome. RESULTS: There were no significant differences in maternal characteristics between the groups. The days gain in utero was no statistically different in the three groups(magnesium sulfate, ritodrine hydrochloride and nifedipine) but markedly longer in the three groups than the control group (p<.01). The total success rate was similar in the three groups, but side effects were much more in the magnesium sulfate and ritodrine group than the nifedipine group (p<.05). The respiratory distress syndrome in neonate was decreased in the three groups than the control group without statistical significance. CONCLUSION: Nifedipine is an effective, safe, and well-tolerated tocolytic agent. In this retrospective study, total success rate of controlling preterm labor was similar in the three groups, but patients who received nifedipine were less side effects than magnesium sulfate or ritodrine group.
Subject(s)
Female , Humans , Infant, Newborn , Pregnancy , Bed Rest , Magnesium Sulfate , Magnesium , Nifedipine , Obstetric Labor, Premature , Retrospective Studies , Ritodrine , TocolysisABSTRACT
OBJECTIVES: The purpose of this study was to evaluate the efficacy and safety of magnesium sulfate and ritodrine hydrochloride in the management of preterm labor. METHODS: This study was undertaken to assess the clinical efficacy & safety of magnesium sulfate and ritodrine hydrochloride on 120 patients admitted with preterm labor from Jul. 1, 1996 to Dec. 31, 1998. RESULTS: 1. The incidence of preterm labor was showed 6.0~7.7% of total number of delivery. 2. The risk factors of the preterm labor were premature rupture of membrane, severe preeclampsia, previous preterm delivery, twin pregnancy, placenta previa, fetal anomaly, incompetent cervix, placental abruption, and uterine myoma in order, but 28.6% of preterm labor had no apparent risk factors. 3. The days gained in uterus was not statistically different between the magnesium sulfate group and the ritodrine group (p<0.05) but longer in the two groups than the control group. And the delivery time was also not statistically different between the magnesium sulfate group and the ritodrine group (p<0.01) but significantly increased in the two groups than the control group. 4. The rate of complete and incomplete success was similar as 12.5% and 35% (total success rate 47.5%) in the magnesium sulfate group, 7.5% and 45% (total success rate 52.5%) in the ritodrine group but only 2.5% and 27.5% (total success rate 30%) was showed in the control group. 5. The side effects were much more in the ritodrine group than the magnesium sulfate group. The patients requiring second-line therapy were similar in the both groups but the main cause was uncontrolled uterine contraction in the magnesium sulfate group, and intolerable side effects in the ritodrine group. 6. The pulse rate was not statistically different in magnesium sulfate group but markedly increased in ritodrine group (p<0.05). After managements of preterm labor, the serum potassium and ionized calcium level was significantly decreased in the two groups (p<0.05, p<0.01). CONCLUSION: There was not significantly different efficacy and safety of magnesium sulfate and ritodrine hydrochloride in the management of preterm labor.